目的 研究肾移植患者口服麦考酚钠肠溶片(EC-MPS)达稳态后其活性代谢产物霉酚酸(MPA)的药动学。方法 选取同种异体活体肾移植患者12例(男8例, 女4例)进行研究,所有患者均采用环孢素( CsA) + 麦考酚钠肠溶片(EC-MPS) + 泼尼松( Pred) 的三联用药方案。用高效液相色谱法测定霉酚酸血药浓度,血药浓度数据用DAS2.0软件, 按非房室模型拟合计算药动学参数,并分别用不同时间点的血药浓度与AUC0-12 h作相关性分析。结果 霉酚酸稳态后的药动学参数Tmax为(5.67±3.68)h,ρmax为(11.78±6.21) mgL-1,AUC0-12 h为(44.72±15.22) mghL-1,MRT为(5.54±1.15) h,CLz/F为(0.35±0.15) Lh-1,Vz/F为(2.71±1.25) L,相关性分析显示ρ8 h相关性最好。结论 霉酚酸个体间药动学差异大,建议将ρ8 h作为肾移植术后早期监测MPA的参考指标。
Abstract
OBJECTIVE To determine the steady state pharmacokinetics of mycophenolic acid ( MPA), the active metabolite, after an oral administration of enteric-coated mycophenolate sodium (EC-MPS) in the renal transplant patients.METHODS This study was conducted in 12 Chinese renal transplant patients (8 men and 4 women) receiving living donor and treated with EC-MPS, cyclosporine, and corticosteroids. MPA concentrations were measured by high performance liquid chromatography (HPLC). The DAS2.0 pharmaceutical kinetics software was used for the calculation of pharmacokinetic parameters. The correlation of each sampling time for MPA AUC were analyzed. RESULTS The mean time for it to reach peak (tmax), the mean maximum plasma concentration, the mean area under the curve (AUC) from 0 to 12 h, mean residence time (MRT) ,and clearance (CL) were (5.67±3.68)h, (11.78±6.21) mgL-1, (44.72±15.22 ) mghL-1, (5.54±1.15) h, ( 0.35±0.15) Lh-1, respectively. Spearman's correlation coefficients for ρ0 h, ρ6 h, ρ8 h and ρ12 h were 0.414 (P=0.18), 0.716 (P=0.009), 0.755 (P=0.004) and 0.148 (P=0.646).CONCLUSION The PKs of EC-MPS has a high variability among Chinese renal transplant recipients. The ρ8 h to look as a important concentration rather than ρ0 h were proposed.
关键词
麦考酚钠肠溶片 /
霉酚酸 /
肾移植患者 /
药动学
{{custom_keyword}} /
Key words
enteric-coated mycophenolate sodium (EC-MPS) /
mycophenolic acid (MPA) /
renal transplantation patient /
pharmacokinetics
{{custom_keyword}} /
中图分类号:
R969.1
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] BULLINGHAM R ,MONROE S ,NICHOLLS A , et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration[J]. J Clin Pharmacol,1996 ,36 (4) :315-324.[2] LANGONE A J, CHAN L, BOLIN P, et al. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: A multicenter, double-blind, randomized study [J].Transplantation, 2011,91(4):470-478. [3] CHAN L, MULGAONKAR S, WALKER R,et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium [J]. Transplantation,2006,81(9):1290-1298.[4] REYES H, HERNNDEZ A M, VALVERDE S, et al. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children [J]. Pediatr Transplantation, 2010,14(6): 746-752.[5] LU X Y, HUANG H F, HUANG M Z, et al. Pharmacokinetics study of mycophenolate mofetil in renal transplantation patients[J]. Chin Pharm J (中国药学杂志), 2005,40(16):1246-1248.[6] SHI S J, LI Z F, WAN Y S, et al. Pharmacokinetics and bioequivalence of mycophenolate Mofetil dispersible Tablets in healthy volunteers [J]. Chin Pharm J (中国药学杂志), 2008, 43(10):776-779.[7] QIU K,TIAN H, WANG W, et al. Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients[J].Chin Med J, 2012,125(23):4226-4232.[8] SUMETHKUL V, NA-BANGCHANG K, KANTACHUVESIRI S, et al. Standard dose enteric-coated mycophenolate sodium (EC-MPS) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients[J].Transplant Proc, 2005, 37(2):861-863.[9] CAPONE D, TARANTINO G, KADILLI I, et al. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving entericcoated mycophenolate sodium(EC-MPS) and cyclosporine [J]. Nephrol Dial Transplant,2011,26(9):3019-3025.[10] SOMMERER C, KREBS S M, SCHAIER M, et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: Limited sampling strategies and clinical outcome in renal transplant patients [J]. Br J Clin Pharmacol, 2010,69(4):346-357.[11] YU Z C, ZHAO J P, XU D, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients after first dosing and in steady-state [J]. Chin J Clin Pharmacol(中国临床药理学杂志),2004, 2(1):205-209.[12] BUDDE K, GLANDER P, DIEKMANN F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium[J]. Expert Opin Pharmacother, 2004, 5(6):1333-1345.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}